Print this Page
E-mail This Page
Fox Chase Cancer Center Appoints Louis M. Weiner, M.D. Vice President of Translational Research
PHILADELPHIA (August 12, 2002) -Louis M. Weiner, M.D, has been appointed Fox Chase Cancer Center's new vice president for the translational research. Weiner, who occupies the G. Morris Dorrance Jr. Endowed Chair, will also remain in his current role as chairman of the department of medical oncology.
Translational research describes the scientific process of developing new therapies-from the laboratory until the agents have completed testing in human clinical trials. This new position will provide a focus for obtaining needed resources, which could accelerate the pace of translational research at Fox Chase Cancer Center.
Robert C. Young, M.D., president of Fox Chase, is confident that Weiner will easily meet the challenges of his new position. "He is passionate and enthusiastic about the importance of translational research within Fox Chase," Young said.
"He is deeply committed to helping investigators identify collaborations and to obtaining the institutional and financial support to stimulate such research." Weiner's selection received full support from Fox Chase Cancer Center's board of directors.
Weiner specializes in treating patients with advanced gastrointestinal cancers as well as conducting research on innovative cancer therapies, such as those that mobilize a patient's own immune system to fight the disease. Young called Weiner "one of Fox Chase's most successful translational researchers."
The responsibilities of the new vice president for translational research include the stimulation of interactive grants, startup funding for translational research collaborations, developmental funds for ongoing translational research, creation of an institutional forum for discussion and presentation of interactive research.
Weiner chairs a new translational research committee composed of two members from the three research divisions-basic, medical and population science. He will be responsible for monitoring the Specialized Program of Research Excellence (SPORE) and Center of Excellence programs funded by the National Cancer Institute. He will also chair the review committee that distributes translational research funds from Fox Chase's cancer center support grants from NCI. He will also assume responsibility for the interactive portions of this grant.
Weiner is Fox Chase's principal investigator for the Eastern Cooperative Oncology Group, a national study group that conducts clinical trials. He chairs its committee on biologic response modifiers and its translational research committee.
Weiner received his M.D. from Mount Sinai School of Medicine in New York City. After clinical and research fellowships at Tufts University School of Medicine, he came to Fox Chase in 1984. He has served as chairman of medical oncology since 1994 and has been section chief of medical oncology for Temple University School of Medicine since 1998.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.
For additional assistance, please contact